1. Home
  2. GVH vs XRTX Comparison

GVH vs XRTX Comparison

Compare GVH & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

HOLD

Current Price

$1.10

Market Cap

2.7M

Sector

N/A

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$0.39

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVH
XRTX
Founded
2016
2011
Country
Australia
Canada
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.7M
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
GVH
XRTX
Price
$1.10
$0.39
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$80.00
N/A
AVG Volume (30 Days)
2.8M
114.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102,768.97
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.38
52 Week High
$10.74
$1.41

Technical Indicators

Market Signals
Indicator
GVH
XRTX
Relative Strength Index (RSI) 45.25 28.21
Support Level $0.88 $0.38
Resistance Level $1.80 $0.60
Average True Range (ATR) 0.17 0.04
MACD 0.07 -0.00
Stochastic Oscillator 32.10 8.80

Price Performance

Historical Comparison
GVH
XRTX

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: